November 18, 2016 - By Marguerite Chambers · 0 Comments
The stock of Trevena Incorporated (NASDAQ:TRVN) registered an increase of 3.43% in short interest. TRVN’s total short interest was 1.57M shares in November as published by FINRA. Its up 3.43% from 1.52 million shares, reported previously. With 239,200 shares average volume, it will take short sellers 7 days to cover their TRVN’s short positions. The short interest to Trevena Incorporated’s float is 4.58%. The stock decreased 0.63% or $0.04 during the last trading session, hitting $6.32. Trevena Inc (NASDAQ:TRVN) has declined 30.93% since April 18, 2016 and is downtrending. It has underperformed by 35.36% the S&P500.
Trevena Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $345.42 million. The Firm discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors . It currently has negative earnings. Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.
Out of 7 analysts covering Trevena Inc (NASDAQ:TRVN), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. Trevena Inc has been the topic of 10 analyst reports since August 3, 2015 according to StockzIntelligence Inc. Cowen & Co maintained Trevena Inc (NASDAQ:TRVN) rating on Tuesday, September 1. Cowen & Co has “Outperform” rating and $14 price target. The company was maintained on Tuesday, August 11 by Needham. The firm has “Buy” rating given on Wednesday, March 2 by WallachBeth Capital. JMP Securities maintained it with “Market Outperform” rating and $18 target price in Wednesday, March 9 report. On Monday, August 3 the stock rating was initiated by Brean Capital with “Buy”. The company was maintained on Wednesday, September 2 by JMP Securities. The stock has “Equal-Weight” rating given by Barclays Capital on Tuesday, September 1. FBR Capital initiated the shares of TRVN in a report on Tuesday, March 29 with “Outperform” rating.
Trevena Inc., incorporated on November 9, 2007, is a clinical-stage biopharmaceutical company. The Firm discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. In addition to these three product candidates, it has identified and has completed the Phase I program for TRV734, an orally administered clinical compound expected to be used for first-line treatment of moderate to severe acute and chronic pain.
Another recent and important Trevena Inc (NASDAQ:TRVN) news was published by Businesswire.com which published an article titled: “Trevena, Inc. Receives FDA Breakthrough Therapy Designation for Oliceridine …” on February 22, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marguerite Chambers